HSBC Holdings 13F: Cuts Cardinal Health (CAH) Stake by $22M
HSBC Holdings reduced its position in Cardinal Health by 15.1%, cutting 92,629 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
HSBC Holdings sold 92,629 shares from its stake in Cardinal Health, Inc. ($CAH), a 15.12% decrease, according to a 13F filing with the SEC dated April 30, 2026. It reported 519,844 shares worth $123.49 million at the end of the quarter.
Since the filing, $CAH is down 3.9% after 1 week, up 1.2% after 1 month and up 32.3% to date (from the $192.01 close on Apr 30, 2026).
CAH
Cardinal Health, Inc.
Key Points
- HSBC Holdings reduced its stake in Cardinal Health by 92,629 shares, bringing its total to 519,844 shares valued at $121.1 million.
- Cardinal Health, with a market cap of $52.2 billion, saw its stock trading near $233.01 on Thursday, with a P/E ratio of 34.06.
- Analyst firms like Citigroup and TD Cowen maintained buy ratings, with price targets of $245 and $255 respectively.
Get $CAH trade alerts by text
We text you when insiders, Congress or big funds trade $CAH. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cardinal Health, Inc. alert may contain errors. Disclosures
HSBC Holdings has reduced its stake in Cardinal Health, Inc. (NYSE: CAH) by 92,629 shares, according to its latest Form 13F filing with the SEC. This cut represents a 15.1% decrease in its holdings, leaving HSBC with 519,844 shares valued at approximately $121.1 million as of the reporting period.
HSBC Holdings vs. the S&P 500
Hypothetical returns from HSBC Holdings's disclosed trades, not real profit or advice. How we model this.
What Changed in HSBC Holdings' Cardinal Health Position
HSBC Holdings trimmed its position in Cardinal Health by 92,629 shares, decreasing its stake by 15.1% to a total of 519,844 shares. The value of these holdings is now about $121.1 million. This move was reported in the fund's recent 13F filing, reflecting its holdings as of the end of the reporting period.
Other Institutional Activity in Cardinal Health
Several other institutional investors made moves in Cardinal Health. BlackRock, Inc. reduced its holdings by 146,765 shares, ending with 28,494,855 shares valued at about $6.02 billion, a 0.5% decrease. Vanguard Capital Management LLC opened a new position with 15,288,709 shares worth approximately $3.23 billion. Similarly, Vanguard Portfolio Management LLC also initiated a new position, holding 13,732,309 shares valued at around $2.90 billion. State Street Corp cut its stake by 434,712 shares, a 3.5% reduction, ending with 12,074,518 shares worth $2.55 billion. Geode Capital Management, LLC added 51,519 shares, a 0.8% increase, bringing its total to 6,580,532 shares valued at about $1.39 billion.
Cardinal Health, Inc. Stock Down 6.4%
Shares of NYSE:CAH traded near $233.01 on Thursday. Cardinal Health boasts a market capitalization of $52.2 billion, with a P/E ratio of 34.06 and a forward P/E of 18.57. The stock has a 52-week range between $137.75 and $233.6, with a 50-day moving average of $203.73 and a 200-day moving average of $197.28. The company's beta is 0.526, signaling lower volatility compared to the market.
Recent Earnings
Cardinal Health reported revenue of $250.7 billion, reflecting a growth of 11%. The company posted an EPS of $6.54 with a net margin of 0.62%. The return on equity stood at a modest level. Investors can expect the next earnings announcement on August 18, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health offers an annual dividend rate of $2.05, yielding 0.92%. The dividend payout ratio is 31.2%, indicating a sustainable distribution of earnings to shareholders.
Insider Buying and Selling at Cardinal Health, Inc.
On April 15, 2026, Patricia Hemingway Hall acquired 381 shares at an average price of $207.83. Earlier, on February 27, 2026, Michelle Greene, the Chief Information Officer, sold 2,746 shares at an average price of $228.47. Aaron Alt, the Chief Financial Officer, sold a total of 4,656 shares across multiple transactions in February 2026, at prices ranging from $220.79 to $225.5.
Analysts Set New Price Targets
On May 4, 2026, JP Morgan maintained a hold rating with a price target of $215. Citigroup and TD Cowen, on May 1, 2026, both maintained buy ratings, setting targets at $245 and $255, respectively. Wells Fargo also maintained its buy rating with a $245 target. The consensus among 15 analysts is a strong buy, with a mean target price of $245.27.
About Cardinal Health
Cardinal Health, Inc., headquartered in Dublin, Ohio, is a key player in the healthcare services and products industry. It operates through two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, pharmacies, and other healthcare providers, distributing a wide range of pharmaceutical and medical products. Cardinal Health also offers services to pharmaceutical manufacturers and healthcare providers, including pharmacy management and supply chain solutions. Under the leadership of CEO Jason M. Hollar, the company employs over 53,000 people.
Bottom Line
HSBC Holdings' decision to cut its stake in Cardinal Health by 15.1% highlights the ongoing adjustments in institutional portfolios. Investors often track such filings to gauge sentiment and positioning among major funds. It's important to remember that 13F filings reflect past holdings and may not indicate current positions.
Related Filing Alerts
Source: HSBC Holdings's 13F filing on $CAH (Apr 30, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: HSBC Holdings 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts